Skip to main content

QGEN · Qiagen N.V.

Track QGEN — free
$49.57 -0.06 (-0.12%)
Market Cap
$10.25B
Shares
206.50M
Volume · Nov 20 674.62K Avg daily vol (3M) 3.68M

Price & Indicators

 

Key stats

Close
$49.63
Thu 19 Nov
Open
$49.73
Thu 19 Nov
Average volume, 30 days
5.1M
shares a session
Short interest
6.4M
3.1% of shares · 1.0 days to cover
Day range
$49.41$49.76
Open $49.73 Close $49.63
52-week closing range
$32.63$55.66
Close $49.63 10.8% under the high
Short volume, last session
50%
Last earnings
Nov 4, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 6
Current report 6-K
Sales rise while net income declines

QIAGEN N.V. reported net sales of $547,869 thousand and net income of $105,659 thousand for the three months ended September 30, 2026, compared with $532,583 thousand and $130,043 thousand for the three months ended September 30, 2025.

Read from the first part of this long document
4 source passages
QIAGEN N.V. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) Three Months Ended September 30, 2026 2025 Net sales | (4) | $547,869 | $532,583 | $1,575,229 | $1,549,579 Net income | | $105,659 | $130,043 | $277,103 | $317,051 Open the document at this passage
Nov 6
Current report 6-K
Sales rose 3%, reaching $548 million; outlook suspended pending EQT

QIAGEN reported Q3 2026 net sales of $548 million, up 3% and 3% at constant exchange rates. Adjusted diluted EPS reached $0.65, but it suspended its 2026 outlook and withdrew guidance while the EQT Private Equity acquisition remains pending.

4 source passages
QIAGEN reports full Q3 2026 results Net sales of $548 million rise 3% and also 3% at constant exchange rates (CER) Diluted EPS of $0.51; adjusted diluted EPS of $0.65 ($0.65 CER) Due to the pending transaction with EQT Private Equity, QIAGEN has suspended its 2026 outlook and will not provide financial guidance while the transaction is pending Open the document at this passage
Oct 28
Tender offer SC TO-C
Planned €46.50 per share cash tender offer for ordinary shares

Crown NL Bidco B.V., a wholly owned subsidiary of Crown NL Midco B.V., plans a tender offer to acquire all QIAGEN N.V. ordinary shares at €46.50 per share in cash under a Business Combination Agreement dated October 21, 2026. The tender offer has not yet commenced and will be made under German law, pursuant to an offer document approved by BaFin.

4 source passages
to acquire all of the issued ordinary shares, par value €0.01 per share, of QIAGEN N.V. at a price of €46.50 per share, in cash, without interest, pursuant to a Business Combination Agreement, dated as of October 21, 2026 The tender offer referenced herein has not yet commenced. the offer document and related offer materials prepared by the Offeror and as approved by the German Federal Financial Supervisory Authority Open the document at this passage
Oct 23
Current report 6-K
Crown NL Bidco agrees to tender offer for Qiagen at €46.50 per share in cash

Qiagen N.V. reported a Business Combination Agreement dated October 21, 2026, under which Crown NL Bidco B.V. plans a tender offer for all issued ordinary shares at €46.50 per share in cash, without interest. The tender offer has not yet commenced and is subject to BaFin clearance and the agreement's conditions.

Read from the first part of this long document
3 source passages
The related ad hoc announcement dated October 21, 2026 is attached as Exhibit 99.2 hereto and is incorporated herein by reference. at a price of €46.50 per share, in cash, without interest, pursuant to a Business Combination Agreement, dated as of October 21, 2026 The tender offer referenced herein has not yet commenced. Open the document at this passage
Oct 22
Tender offer SC TO-C
Crown NL Bidco offers €46.50 cash per share in takeover

Crown NL Bidco B.V. decided on 21 October 2026 to make a voluntary cash public takeover offer of €46.50 per QIAGEN share, a 40.3% premium to the €33.15 XETRA closing price on 8 July 2026. The QIAGEN boards agreed to fully support and recommend the offer, with closing expected mid 2027 subject to a minimum acceptance threshold of 50% of outstanding share capital plus one share.

Read from the first part of this long document
6 source passages
On 21 October 2026, Crown NL Bidco B.V. The Bidder will offer QIAGEN shareholders €46.50 in cash for each QIAGEN share which represents an attractive premium of 40.3% to the XETRA closing price of €33.15 per QIAGEN share on 8 July 2026 agreed to fully support the Takeover Offer and to recommend the Takeover Offer for acceptance to the QIAGEN shareholders. The Takeover Offer will be subject to a minimum acceptance threshold of 50% of the Company’s outstanding share capital plus one QIAGEN Share Closing of the Takeover Offer is currently expected for mid 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+5.7%
Year over year
Operating margin
22.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$555.51M
Latest balance sheet
Dividend yield
5.3%
Trailing 12 months
Shares change YoY
-2.6%
Year over year · fewer shares
Price change (1Y)
+11.7%
Trailing year
Short interest
3.1%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg +5%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 74%
mid-range
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +37%
trailing
YTD return +10%
this year
Relative strength +43%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $47 › 200d $42 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +67 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.10% of shares out · ▼ -11.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
372 holders — near 3-yr high, broad support
Squeeze score 43
elevated · 0–100
Fundamentals
Excellent
Revenue growth +6%
Y/Y
Gross margin 62%
expanding
EPS growth +424%
Y/Y
Free cash flow $453.3M
Buyback $100.0M
authorized
Balance sheet $815.4M
net debt
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −41%
past year
ATR 1.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 6, 2026
Total net sales growth · full year 2026 1% – 2%
Adjusted diluted EPS · full year 2026 Non-GAAP $2.43
Previous outlook earlier release · from the Earnings Call filed Apr 28, 2026

Still-open targets the latest release did not restate under the same label.

Net sales growth · full year 2026 1% – 2%
Quantiferon sales · full year 2026 $500M
Adjusted diluted earnings per share · full year 2026 at least $2.43
Adjusted EBIT margin · full year 2026 29.5%
Sales growth · second half 2026 4%
CR growth · the year overall 1% – 2%
Pillars of the group growth · 26 7%
Adjusted EBIT margin · full year 29.5%
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Total net sales growth · third quarter 2026 1% – 2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
74% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $47 › 200d $42 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +67 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.10% of shares out · ▼ -11.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
372 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $33 Now $50 · 74% Range high $56
vs 200-day avg +17% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QGEN
Qiagen N.V.
this stock
$10.25B +10.4% +5.7% — 3.1%
TMO
Thermo Fisher Scientific Inc.
$255.19B +18.9% +14.5% 36.3 1.3%
DHR
Danaher Corp
$160.10B -0.6% +8.5% 37.2 1.2%
IDXX
Idexx Laboratories Inc
$54.33B +1.9% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$49.43B +28.9% +6.4% 34.5 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
372
% held
69.7%
Net QoQ
-2.0M sh
Top holder
PRICE T ROWE ASSOCIATES I…
Held Float
View
Held by Funds
Fund positions
109
View
Short & Settlement
Short Interest Falling
Shares short
6.4M
Days to cover
1.0d
Change
-798.0K sh
View
Short Volume
Short vol %
50%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
299
Value
$15.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
34.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Peter Welch
Amount
$1.0K–$15.0K
Traded
Mar 24, 2020
View
Financials
Financials
Revenue (FY)
$2.1B
Net income (FY)
$424.9M
EPS diluted
$1.94
View
Buybacks
Authorized
$100.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 6, 2026
This year
19

QIAGEN reported Q3 2026 net sales of $548 million, up 3% and 3% at constant exchange rates. Adjusted diluted EPS reached $0.65, but it suspended its 2026 outlook and withdrew guidance while the EQT Private Equity acquisition remains pending.

View
Proposed Sales
Value
$1.2M
Shares
25.0K
Filed
Aug 15, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 6, 2026
View
Investor Relations
Latest news
QIAGEN shareholders overwhelmingl…
Published
Nov 6, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
QGEN -0.9% -1.2% +37.2% -1.2% +10.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +4.5% +5.1% +42.8% +4.1% +5.4%

Capital returns

Latest dividend
$0.35 / share · ex Jul 7, 2026
Cut 84.7%
Paid (TTM)
$2.64 / share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in
Full dividend history
Buyback program · as of Jul 12, 2021
Authorized
$100.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1015820 CUSIP N72482156 13F (30d) 361 filings 330 filers Visit website Investor relations